BChE-IN-41 is a highly selective butyrylcholinesterase (BChE) inhibitor with an IC50 of 12 nM and a Ki of 6.6 nM. It exhibits significant brain permeability, with a brain-to-plasma ratio of 9.0. BChE-IN-41 enhances cognitive function in mice with scopolamine and Aβ1-42-induced symptoms of Alzheimer's disease.

AChE (human):22110 nM

BChE-IN-41 (Compound (R)-(−)-3) exhibits neuroprotective activity by reducing SH-SY5Y cell death induced by Aβ 1-42, when used at a concentration of 5 μM for 48 hours.

BChE-IN-41 (Compound (R)-(−)-3) demonstrates high efficacy and brain penetration at doses ranging from 10-100 mg/kg (i.g, single dose) in wild-type Balb/c mice, exhibiting low toxicity without histopathological changes. At doses of 1-10 mg/kg (i.p, single dose), it enhances contextual and recognition memory deficits in scopolamine-induced adult male CD-1 mice. Furthermore, daily administration of 10 mg/kg (i.p) for 14 days improves learning and cognitive function in Aβ 1-42 oligomer-induced male ICR mice.